[go: up one dir, main page]

MX360718B - Purinas macrocíclicas para el tratamiento de infecciones víricas. - Google Patents

Purinas macrocíclicas para el tratamiento de infecciones víricas.

Info

Publication number
MX360718B
MX360718B MX2015000513A MX2015000513A MX360718B MX 360718 B MX360718 B MX 360718B MX 2015000513 A MX2015000513 A MX 2015000513A MX 2015000513 A MX2015000513 A MX 2015000513A MX 360718 B MX360718 B MX 360718B
Authority
MX
Mexico
Prior art keywords
viral infections
treatment
macrocyclic
purines
macrocyclic purines
Prior art date
Application number
MX2015000513A
Other languages
English (en)
Other versions
MX2015000513A (es
Inventor
Jean-François Bonfanti
Jérôme Michel Claude Fortin
Philippe Muller
Frédéric Marc Maurice Doublet
Pierre Jean-Marie Bernard Raboisson
Eric Pierre Alexandre Arnoult
Original Assignee
Janssen Sciences Ireland Uc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Sciences Ireland Uc filed Critical Janssen Sciences Ireland Uc
Publication of MX2015000513A publication Critical patent/MX2015000513A/es
Publication of MX360718B publication Critical patent/MX360718B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La invención se refiere a derivados de purina macrocíclicos que tienen la formula (I), a procesos para su preparación, a composiciones farmacéuticas y a su uso en el tratamiento de infecciones víricas.
MX2015000513A 2012-07-13 2013-07-12 Purinas macrocíclicas para el tratamiento de infecciones víricas. MX360718B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12176330 2012-07-13
PCT/EP2013/064763 WO2014009509A1 (en) 2012-07-13 2013-07-12 Macrocyclic purines for the treatment of viral infections

Publications (2)

Publication Number Publication Date
MX2015000513A MX2015000513A (es) 2015-05-15
MX360718B true MX360718B (es) 2018-11-13

Family

ID=48782357

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015000513A MX360718B (es) 2012-07-13 2013-07-12 Purinas macrocíclicas para el tratamiento de infecciones víricas.

Country Status (28)

Country Link
US (2) US10280180B2 (es)
EP (1) EP2872515B1 (es)
JP (1) JP6250046B2 (es)
KR (1) KR102207888B1 (es)
CN (1) CN104703990B (es)
AU (1) AU2013288600B2 (es)
BR (1) BR112015000615B1 (es)
CA (1) CA2874800C (es)
CL (1) CL2015000080A1 (es)
CY (1) CY1117971T1 (es)
DK (1) DK2872515T3 (es)
EA (1) EA035790B1 (es)
ES (1) ES2590508T3 (es)
HR (1) HRP20161125T1 (es)
HU (1) HUE030685T2 (es)
IL (1) IL235990B (es)
LT (1) LT2872515T (es)
MX (1) MX360718B (es)
MY (1) MY167797A (es)
NZ (1) NZ702364A (es)
PH (1) PH12015500073B1 (es)
PL (1) PL2872515T3 (es)
PT (1) PT2872515T (es)
SG (1) SG11201408542VA (es)
SI (1) SI2872515T1 (es)
UA (1) UA113651C2 (es)
WO (1) WO2014009509A1 (es)
ZA (1) ZA201500186B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3590928T1 (sl) 2011-04-08 2021-10-29 Janssen Sciences Ireland Unlimited Co Derivati pirimidina za zdravljenje virusnih okužb
PH12014501045B1 (en) 2011-11-09 2019-01-16 Janssen Sciences Ireland Uc Purine derivatives for the treatment of viral infections
MX360718B (es) 2012-07-13 2018-11-13 Janssen Sciences Ireland Uc Purinas macrocíclicas para el tratamiento de infecciones víricas.
PL2906563T3 (pl) 2012-10-10 2018-10-31 Janssen Sciences Ireland Uc Pochodne pirolo[3,2-d]pirymidyny do leczenia infekcji wirusowych i innych chorób
KR102253773B1 (ko) 2012-11-16 2021-05-20 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 바이러스 감염 치료를 위한 헤테로사이클릭 치환된 2-아미노-퀴나졸린 유도체
EP2958900B1 (en) 2013-02-21 2019-04-10 Janssen Sciences Ireland Unlimited Company 2-aminopyrimidine derivatives for the treatment of viral infections
JP6336036B2 (ja) 2013-03-29 2018-06-06 ヤンセン・サイエンシズ・アイルランド・ユーシー ウイルス感染治療のための大環状デアザプリノン
CA2911259A1 (en) 2013-05-06 2014-11-13 Merck Patent Gmbh Macrocycles as kinase inhibitors
EP3004074B1 (en) 2013-05-24 2017-10-25 Janssen Sciences Ireland UC Pyridone derivatives for the treatment of viral infections and further diseases
US10385054B2 (en) 2013-06-27 2019-08-20 Janssen Sciences Ireland Unlimited Company Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases
DK3027624T3 (en) 2013-07-30 2019-01-07 Janssen Sciences Ireland Uc THIENO [3,2-D] PYRIMIDINE DERIVATIVES FOR TREATING VIRUS INFECTIONS
PL417066A1 (pl) 2016-05-04 2017-11-06 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne
EP3478688A1 (en) 2016-07-01 2019-05-08 Janssen Sciences Ireland Unlimited Company Dihydropyranopyrimidines for the treatment of viral infections
EP3519406B1 (en) 2016-09-29 2022-02-23 Janssen Sciences Ireland Unlimited Company Pyrimidine prodrugs for the treatment of viral infections and further diseases
US10472361B2 (en) 2017-08-16 2019-11-12 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a benzotriazole moiety, conjugates thereof, and methods and uses therefor
US10487084B2 (en) 2017-08-16 2019-11-26 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a heterobiaryl moiety, conjugates thereof, and methods and uses therefor
US10508115B2 (en) 2017-08-16 2019-12-17 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor
US10494370B2 (en) 2017-08-16 2019-12-03 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor
US10457681B2 (en) 2017-08-16 2019-10-29 Bristol_Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a tricyclic moiety, conjugates thereof, and methods and uses therefor
JP2021035910A (ja) * 2017-11-01 2021-03-04 大日本住友製薬株式会社 置換プリン化合物
TW201945003A (zh) 2018-03-01 2019-12-01 愛爾蘭商健生科學愛爾蘭無限公司 ２，４－二胺基喹唑啉衍生物及其醫學用途
WO2019209811A1 (en) * 2018-04-24 2019-10-31 Bristol-Myers Squibb Company Macrocyclic toll-like receptor 7 (tlr7) agonists
US11554120B2 (en) 2018-08-03 2023-01-17 Bristol-Myers Squibb Company 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor
KR102163494B1 (ko) * 2018-10-26 2020-10-08 한국과학기술연구원 단백질 키나아제 저해제인 헤테로방향족 매크로시클릭 유도체
CN115643805B (zh) 2020-01-27 2024-11-08 百时美施贵宝公司 作为Toll样受体7(TLR7)激动剂的1H-吡唑并[4,3-d]嘧啶化合物
KR20220132594A (ko) 2020-01-27 2022-09-30 브리스톨-마이어스 스큅 컴퍼니 톨-유사 수용체 7 (TLR7) 효능제로서의 1H-피라졸로[4,3-d]피리미딘 화합물
CN115210235A (zh) 2020-01-27 2022-10-18 百时美施贵宝公司 作为Toll样受体7(TLR7)激动剂的1H-吡唑并[4,3-d]嘧啶化合物
CN115135654A (zh) 2020-01-27 2022-09-30 百时美施贵宝公司 作为Toll样受体7(TLR7)激动剂的1H-吡唑并[4,3-d]嘧啶化合物
EP4097108A1 (en) 2020-01-27 2022-12-07 Bristol-Myers Squibb Company 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
JP2023512206A (ja) 2020-01-27 2023-03-24 ブリストル－マイヤーズ スクイブ カンパニー トール様受容体７（ＴＬＲ７）アゴニストとしての１Ｈ－ピラゾロ［４，３－ｄ］ピリミジン化合物
EP4097107A1 (en) 2020-01-27 2022-12-07 Bristol-Myers Squibb Company C3-substituted 1h-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (tlr7) agonists
JP7712941B2 (ja) 2020-01-27 2025-07-24 ブリストル－マイヤーズ スクイブ カンパニー トール様受容体７（ＴＬＲ７）アゴニストとしての１Ｈ－ピラゾロ［４，３－ｄ］ピリミジン化合物
EP4097106A1 (en) 2020-01-27 2022-12-07 Bristol-Myers Squibb Company 1h-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (tlr7) agonists
CN114315861A (zh) * 2020-09-27 2022-04-12 上海维申医药有限公司 大环tlr7激动剂、其制备方法、药物组合物及其用途
CN119192199A (zh) * 2023-06-27 2024-12-27 浙江养生堂天然药物研究所有限公司 含多芳基的大环化合物及其用途

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2610889B2 (ja) * 1987-09-03 1997-05-14 日本臓器製薬株式会社 新規架橋アデニン誘導体
JP4667543B2 (ja) 1996-07-03 2011-04-13 大日本住友製薬株式会社 新規プリン誘導体
TR199900389T2 (xx) 1996-08-28 2000-06-21 Pfizer Inc. �kame edilmi� 6,5-hetero-bisiklik t�revleri.
DE69717867T2 (de) 1996-10-04 2003-10-02 Kyorin Pharmaceutical Co., Ltd. Pyrazolopyridylpyrazinon-derivate und ein verfahren zu ihrer herstellung
AR012634A1 (es) 1997-05-02 2000-11-08 Sugen Inc Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
US6339089B2 (en) 1997-08-13 2002-01-15 Fujirebio Inc. Pyrimidine nucleus-containing compound and a medicament containing the same for a blood oxygen partial pressure amelioration, and a method for preparing the same
CA2311742C (en) 1997-11-28 2009-06-16 Sumitomo Pharmaceuticals Co., Ltd. 6-amino-9-benzyl-8-hydroxypurine derivatives
TW572758B (en) 1997-12-22 2004-01-21 Sumitomo Pharma Type 2 helper T cell-selective immune response inhibitors comprising purine derivatives
US6187777B1 (en) 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
US6200977B1 (en) 1998-02-17 2001-03-13 Tularik Inc. Pyrimidine derivatives
US6110929A (en) 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
JP4342007B2 (ja) 1998-08-10 2009-10-14 大日本住友製薬株式会社 キナゾリン誘導体
JP4315300B2 (ja) 1998-08-10 2009-08-19 大日本住友製薬株式会社 新規なキナゾリン誘導体
US6458798B1 (en) 1998-08-27 2002-10-01 Sumitomo Pharmaceuticals Company, Limited Bicyclic pyrimidine compounds and therapeutic use thereof
US6583148B1 (en) 1999-04-08 2003-06-24 Krenitsky Pharmaceuticals, Inc. Neurotrophic substituted pyrimidines
CA2323008C (en) 1999-10-11 2005-07-12 Pfizer Inc. Pharmaceutically active compounds
WO2002088079A2 (en) 2001-05-01 2002-11-07 Bristol-Myers Squibb Company Dual inhibitors of pde 7 and pde 4
WO2003055890A1 (en) 2001-12-21 2003-07-10 Bayer Pharmaceuticals Corporation Thienopyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
US7091232B2 (en) 2002-05-21 2006-08-15 Allergan, Inc. 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
TW200407143A (en) 2002-05-21 2004-05-16 Bristol Myers Squibb Co Pyrrolotriazinone compounds and their use to treat diseases
JPWO2003104230A1 (ja) 2002-06-07 2005-10-06 協和醗酵工業株式会社 二環性ピリミジン誘導体
WO2004029054A1 (ja) * 2002-09-27 2004-04-08 Sumitomo Pharmaceuticals Company, Limited 新規アデニン化合物及びその用途
US8455458B2 (en) 2002-10-16 2013-06-04 Arthrodynamic Technologies, Animal Health Division, Inc. Composition and method for treating connective tissue damage
CA2528774A1 (en) 2003-06-20 2005-01-27 Coley Pharmaceutical Gmbh Small molecule toll-like receptor (tlr) antagonists
JP2007504232A (ja) 2003-09-05 2007-03-01 アナディス ファーマシューティカルズ インク Ｃ型肝炎ウイルス感染治療用のｔｌｒ７リガンド及びそのプロドラッグの投与
EP1728792A4 (en) 2004-03-26 2010-12-15 Dainippon Sumitomo Pharma Co 8-OXOADENINE COMPOUND
TWI392678B (zh) 2004-03-26 2013-04-11 Dainippon Sumitomo Pharma Co ９-取代-８-氧基腺嘌呤化合物
WO2007084413A2 (en) 2004-07-14 2007-07-26 Ptc Therapeutics, Inc. Methods for treating hepatitis c
JP5031564B2 (ja) 2004-08-10 2012-09-19 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｈｉｖ抑制１，２，４−トリアジン−６−オン誘導体
BRPI0517559A (pt) 2004-11-09 2008-10-14 Hoffmann La Roche composto, processo para a sua preparação, método para o tratamento terapêutico e/ou profilático de enfermidades que são moduladas por inibidores de ptb-1b e utilização dos compostos
US7498409B2 (en) 2005-03-24 2009-03-03 Schering Corporation Screening assay for TLR7, TLR8 and TLR9 agonists and antagonists
EA200702235A1 (ru) 2005-05-04 2008-04-28 Пфайзер Лимитед Производные 2-амидо-6-амино-8-оксопурина в качестве модуляторов toll-подобных рецепторов для лечения рака и вирусных инфекций, таких как гепатит с
TW200716631A (en) 2005-05-12 2007-05-01 Tibotec Pharm Ltd Pyrido[2,3-d]pyrimidines useful as HCV inhibitors, and methods for the preparation thereof
US7994360B2 (en) 2005-05-16 2011-08-09 Xtl Biopharmaceuticals Ltd. Benzofuran compounds
CA2619919C (en) 2005-09-01 2014-04-01 F. Hoffmann-La Roche Ag Diaminopyrimidines as p2x3 and p2x2/3 modulators
US20090192153A1 (en) 2005-09-22 2009-07-30 Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan Novel adenine compound
WO2007056208A2 (en) 2005-11-02 2007-05-18 Cytovia, Inc. N-arylalkyl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof
WO2007063934A1 (ja) 2005-12-02 2007-06-07 Mitsubishi Tanabe Pharma Corporation 脂環式複素環化合物
EP1987030B1 (en) 2006-02-17 2011-11-09 Pfizer Limited 3 -deazapurine derivatives as tlr7 modulators
WO2008009078A2 (en) 2006-07-20 2008-01-24 Gilead Sciences, Inc. 4,6-dl- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections
WO2008009077A2 (en) 2006-07-20 2008-01-24 Gilead Sciences, Inc. 4,6-dl- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections
RU2470936C2 (ru) 2006-12-07 2012-12-27 Дженентек, Инк. Соединения-ингибиторы фосфоинозитид 3-киназы и способы применения
AU2007335962B2 (en) 2006-12-20 2012-09-06 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Antiviral indoles
DK2510946T3 (en) 2007-02-07 2015-11-02 Univ California Conjugates of synthetic fluorescent agonists and their applications
JP2008222557A (ja) 2007-03-08 2008-09-25 Kotobuki Seiyaku Kk ピロロ［３，２−ｄ］ピリミジン誘導体及びこれを有効成分とする医薬組成物
JP5480637B2 (ja) 2007-03-19 2014-04-23 アストラゼネカ・アクチエボラーグ Ｔｏｌｌ様受容体（ｔｌｒ７）モジュレーターとしての９−置換−８−オキソ−アデニン化合物
US8044056B2 (en) 2007-03-20 2011-10-25 Dainippon Sumitomo Pharma Co., Ltd. Adenine compound
PE20081887A1 (es) 2007-03-20 2009-01-16 Dainippon Sumitomo Pharma Co Nuevo compuesto de adenina
JP5268120B2 (ja) 2007-05-22 2013-08-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ベンゾイミダゾロンキマーゼ阻害薬
MX2009013832A (es) * 2007-06-29 2010-03-10 Gilead Sciences Inc Derivados de purina y su uso como moduladores del receptor 7 similar a un puente.
BRPI0814939A2 (pt) 2007-08-10 2015-01-27 Glaxosmithkline Llc Entidade química, composição farmacêutica, e, método para tratar uma infecção viral em um mamífero.
AU2008296545B2 (en) 2007-08-28 2011-09-29 Irm Llc 2 -biphenylamino-4 -aminopyrimidine derivatives as kinase inhibitors
WO2009030998A1 (en) 2007-09-05 2009-03-12 Coley Pharmaceutical Group, Inc. Pyrimidine compounds as toll-like receptor (tlr) agonists
PE20091236A1 (es) 2007-11-22 2009-09-16 Astrazeneca Ab Derivados de pirimidina como immunomoduladores de tlr7
CA2710644C (en) * 2007-12-24 2016-03-29 Tibotec Pharmaceuticals Macrocyclic indoles as hepatitis c virus inhibitors
CA2713438A1 (en) 2008-02-07 2009-08-13 The Regents Of The University Of California Treatment of bladder diseases with a tlr7 activator
CN102014911A (zh) * 2008-04-28 2011-04-13 默沙东公司 Hcv ns3蛋白酶抑制剂
US8946239B2 (en) 2008-07-10 2015-02-03 Duquesne University Of The Holy Spirit Substituted pyrrolo, -furano, and cyclopentylpyrimidines having antimitotic and/or antitumor activity and methods of use thereof
UY31982A (es) 2008-07-16 2010-02-26 Boehringer Ingelheim Int Derivados de 1,2-dihidropiridin-3-carboxamidas n-sustituidas
WO2010133885A1 (en) 2009-05-21 2010-11-25 Astrazeneca Ab Novel pyrimidine derivatives and their use in the treatment of cancer and further diseases
TWI468402B (zh) 2009-07-31 2015-01-11 必治妥美雅史谷比公司 降低β－類澱粉生成之化合物
US8637525B2 (en) 2009-07-31 2014-01-28 Bristol-Myers Squibb Company Compounds for the reduction of beta-amyloid production
WO2011049988A2 (en) 2009-10-20 2011-04-28 Eiger Biopharmaceuticals, Inc. Indazoles to treat flaviviridae virus infection
WO2011049825A1 (en) 2009-10-22 2011-04-28 Gilead Sciences, Inc. Derivatives of purine or deazapurine useful for the treatment of (inter alia) viral infections
KR101094446B1 (ko) 2009-11-19 2011-12-15 한국과학기술연구원 단백질 키나아제 저해활성을 가지는 2,4,7-치환된 티에노［3,2-ｄ］피리미딘 화합물
JP2013032290A (ja) 2009-11-20 2013-02-14 Dainippon Sumitomo Pharma Co Ltd 新規縮合ピリミジン誘導体
DE102010040233A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
WO2012067269A1 (en) 2010-11-19 2012-05-24 Dainippon Sumitomo Pharma Co., Ltd. Aminoalkoxyphenyl compounds and their use in the treatment of disease
WO2012066335A1 (en) 2010-11-19 2012-05-24 Astrazeneca Ab Phenol compounds als toll -like receptor 7 agonists
SI3590928T1 (sl) 2011-04-08 2021-10-29 Janssen Sciences Ireland Unlimited Co Derivati pirimidina za zdravljenje virusnih okužb
PH12013502382B1 (en) 2011-05-18 2021-09-22 Janssen Sciences Ireland Uc Quinazoline derivatives for the treatment of viral infections and further diseases
PH12014501045B1 (en) 2011-11-09 2019-01-16 Janssen Sciences Ireland Uc Purine derivatives for the treatment of viral infections
WO2013117615A1 (en) 2012-02-08 2013-08-15 Janssen R&D Ireland Piperidino-pyrimidine derivatives for the treatment of viral infections
SI2841428T1 (sl) 2012-04-24 2018-12-31 Vertex Pharmaceuticals Incorporated Inhibitorji DNA-PK
MX360718B (es) 2012-07-13 2018-11-13 Janssen Sciences Ireland Uc Purinas macrocíclicas para el tratamiento de infecciones víricas.
ES2707885T3 (es) 2012-08-10 2019-04-05 Janssen Sciences Ireland Unlimited Co Alquilpirimidinderivados para el tratamiento de infecciones víricas y otras enfermedades
EP2712866A1 (en) 2012-10-01 2014-04-02 Centre National de la Recherche Scientifique (CNRS) 1,2,4-triazine derivatives for the treatment of viral infections
WO2014053595A1 (en) 2012-10-05 2014-04-10 Janssen R&D Ireland Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases
PL2906563T3 (pl) 2012-10-10 2018-10-31 Janssen Sciences Ireland Uc Pochodne pirolo[3,2-d]pirymidyny do leczenia infekcji wirusowych i innych chorób
KR102253773B1 (ko) 2012-11-16 2021-05-20 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 바이러스 감염 치료를 위한 헤테로사이클릭 치환된 2-아미노-퀴나졸린 유도체
EP2958900B1 (en) 2013-02-21 2019-04-10 Janssen Sciences Ireland Unlimited Company 2-aminopyrimidine derivatives for the treatment of viral infections
JP6336036B2 (ja) 2013-03-29 2018-06-06 ヤンセン・サイエンシズ・アイルランド・ユーシー ウイルス感染治療のための大環状デアザプリノン
DK3027624T3 (en) 2013-07-30 2019-01-07 Janssen Sciences Ireland Uc THIENO [3,2-D] PYRIMIDINE DERIVATIVES FOR TREATING VIRUS INFECTIONS
US9701661B2 (en) 2014-07-11 2017-07-11 Northwestern University 2-imidazolyl-pyrimidine scaffolds as potent and selective inhibitors of neuronal nitric oxide synthase

Also Published As

Publication number Publication date
PH12015500073A1 (en) 2015-03-30
CN104703990A (zh) 2015-06-10
HRP20161125T1 (hr) 2016-11-18
JP2015522058A (ja) 2015-08-03
BR112015000615A2 (pt) 2017-06-27
CN104703990B (zh) 2017-10-13
PT2872515T (pt) 2016-07-27
BR112015000615A8 (pt) 2021-10-19
SG11201408542VA (en) 2015-02-27
HUE030685T2 (en) 2017-05-29
EA035790B1 (ru) 2020-08-11
LT2872515T (lt) 2016-10-10
UA113651C2 (xx) 2017-02-27
IL235990A0 (en) 2015-02-01
CY1117971T1 (el) 2017-05-17
CA2874800C (en) 2021-04-06
PH12015500073B1 (en) 2015-03-30
BR112015000615B1 (pt) 2022-05-31
CA2874800A1 (en) 2014-01-16
IL235990B (en) 2018-12-31
AU2013288600B2 (en) 2017-06-29
DK2872515T3 (en) 2016-09-19
CL2015000080A1 (es) 2015-04-10
ZA201500186B (en) 2017-11-29
KR20150036239A (ko) 2015-04-07
WO2014009509A1 (en) 2014-01-16
HK1207062A1 (en) 2016-01-22
AU2013288600A1 (en) 2014-12-18
KR102207888B1 (ko) 2021-01-26
US10280180B2 (en) 2019-05-07
NZ702364A (en) 2016-09-30
MX2015000513A (es) 2015-05-15
EP2872515A1 (en) 2015-05-20
US10822349B2 (en) 2020-11-03
EP2872515B1 (en) 2016-06-08
ES2590508T3 (es) 2016-11-22
PL2872515T3 (pl) 2017-05-31
JP6250046B2 (ja) 2017-12-20
US20150299221A1 (en) 2015-10-22
MY167797A (en) 2018-09-26
EA201590215A1 (ru) 2015-06-30
SI2872515T1 (sl) 2016-10-28
US20190330234A1 (en) 2019-10-31

Similar Documents

Publication Publication Date Title
PH12015500073A1 (en) Macrocyclic purines for the treatment of viral infections
PH12014501045B1 (en) Purine derivatives for the treatment of viral infections
PH12015502261A1 (en) Macrocyclic deaza-purinones for the treatment of viral infections
MY169159A (en) Piperidino-pyrimidine derivatives for the treatment of viral infections
PH12015500983A1 (en) Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections
PH12015501648B1 (en) 2-aminopyrimidine derivatives for the treatment of viral infections
IN2015MN00478A (es)
PH12015502797A1 (en) THIENO[3,2-d]PYRIMIDINES DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS
PH12015500724A1 (en) 1, 2, 4-triazine derivatives for the treatment of viral infections
PH12015500713A1 (en) Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: JANSSEN SCIENCES IRELAND UC

FG Grant or registration